Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02715609 : Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
PhasePhase 1/Phase 2
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Diagnosis of GBM (WHO grade IV). Patients who are participating in the optional
preoperative pharmacokinetic study, may have presumed GBM based on
clinical/radiological findings. However, patient must have histologically confirmed
GBM before continuing to receive DSF with concurrent RT/TMZ.

- At least 18 years of age.

- Karnofsky performance status (KPS) of at least 60%

- For patients who will participate in the optional pre-operative DSF pharmacokinetic
study, they should be eligible for surgical resection for which at least 0.2 cubic cm
or approximately 200 mg of tumor will be removed in additional to tumor specimen
required for pathology evaluation. Patients enrolled after undergoing surgical
resection or biopsy with histologically confirmed GBM are not required to meet this
point of inclusion.

- Eligible for and planning to receive standard fractionated RT with concurrent TMZ.

- Willing to remain abstinent from consuming alcohol while on DSF.

- Willing to defer definitive surgery for one week while taking DSF and Cu. Patients who
declined the optional pre-operative pharmacokinetic study or enrolled after undergoing
surgical resection or biopsy with histologically confirmed GBM are not required to
meet this point of inclusion.

- Meets the following laboratory criteria:

- Absolute neutrophil count = 1,500/mcL

- Platelets = 100,000/mcL

- Hemoglobin > 10.0 g/dL (transfusion and/or ESA allowed)

- Total bilirubin = 2x institutional upper limit of normal (ULN)

- AST and ALT < 3 x ULN

- Serum creatinine < 1.5 x ULN or creatinine clearance > 50 mL/min (by

- Females of childbearing potential (defined as a female who is non-menopausal or
surgically sterilized) must be willing to use an acceptable method of birth control
(i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom
with spermicide, or abstinence) for the duration of the study. Should a woman become
pregnant or suspect she is pregnant while participating in this study, she must inform
her treating physician immediately.

- Able to take oral medication.

- Able to understand and willing to sign an IRB-approved written informed consent
document (legally authorized representative permitted).

Exclusion Criteria:

- Receipt of any other investigational agents within 14 days prior to study treatment

- Enrolled on another clinical trial testing a novel therapy or drug.

- History of allergic reaction to DSF or Cu.

- Treatment with the following medications are contraindicated with DSF when taken
within 7 days prior to the first dose of DSF + Cu: metronidazole, isoniazid,
dronabinol, carbocisteine, lopinavir, paraldehyde, ritonavir, sertaline, tindazole,
tixanidine, atazanavir. (Note: the following medications are not contraindicated but
should be cautioned if taking concurrently with DSF: warfarin, phenytoin,
theophylline, chlorzoxazone, chlordiazepoxide, diazepam. If the patient is taking
warfarin, INR should be monitored closely. If the patient has to remain on phenytoin,
its serum concentration and response should be monitored closely.

- Active or severe hepatic, cardiovascular, or cerebrovascular disease, including
myocardial infarction within 6 months prior to enrollment, New York Heart Association
(NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active
conduction system abnormalities.

- History of idiopathic seizure disorder, psychosis, or schizophrenia.

- History of Wilson's disease or family member with Wilson's disease.

- History of hemochromatosis or family member with hemochromatosis.

- Pregnant and breastfeeding women will be excluded because of the known teratogenic
effect of RT and the unknown effect of TMZ and DSF on fetal development. Women of
childbearing potential must have a negative pregnancy test within 14 days of
initiation of treatment.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557